NCT02829346

Peri-articular Tranexamic Acid Injection in Total Knee Arthroplasty

Peri-articular Tranexamic Acid Injection in Total Knee Arthroplasty: A Randomized Controlled Trial

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Thammasat University · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

This study evaluates the peri-articular tranexamic acid injection in total knee arthroplasty which is an alternative route of administration for blood loss reduction. Half of participants will receive intravenous tranexamic acid injection, while the other half will receive peri-articular tranexamic acid injection during total knee arthroplasty.

Detailed description

Intravenous tranexamic acid (IV TXA) is one of the most effective agents in use for reducing blood loss following total knee arthroplasty (TKA) but its safety regarding venous thromboembolic events (VTEs) remains in question. The direct, local application of TXA may reduce systemic toxicity whilst maintaining good or better bleeding control compared to IV TXA. The topical application of TXA via Hemovac drains has been reported previously with good results. However, there are no data on peri-articular TXA injections during TKA.

Conditions

• Osteoarthritis, Knee

Interventions

Type	Name	Description
DRUG	Peri-articular tranexamic acid	750 mg of peri-articular TXA, prior to deflating the tourniquet and wound closure
DRUG	Intravenous tranexamic acid	750 mg of IV TXA, prior to deflating the tourniquet and wound closure

Timeline

• Start date: 2012-10-01
• Primary completion: 2013-10-01
• Completion: 2013-10-01
• First posted: 2016-07-12
• Last updated: 2016-07-12

Locations

1 site across 1 country: Thailand